The interaction of canonical Wnt/β-catenin signaling with protein lysine acetylation

Table 2 Information on KAT inhibitors and KDAC inhibitors to suppress Wnt/β-catenin signaling

Drug name	KAT or HDAC specificity	Clinical stage in treating cancer	Target cancer cell models	Effect on Wnt/β-catenin signaling	References
Curcumin	KAT inhibitor	Phase I/II	HCC, Breast cancer, Chronic myeloid leukemia, Colorectal cancer, Colon carcinoma, Intestinal adenoma, Pancreatic cancer, Ovarian carcinoma, Head and neck squamous cell carcinoma	Inhibition	[72, 73]
Garcinol	KAT inhibitor	Preclinical	Non-small cell lung carcinomas, Breast cancer	Inhibition	[74, 75]
ICG-001	KAT inhibitor	Phase I/II	Osteosarcoma, Pancreatic cancer, HCC, Nasopharyngeal carcinoma, Uveal melanoma, Colorectal cancer, Lung cancer, glioma, Myeloma, Gastric cancer, Acute lymphoblastic leukemia	Inhibition	[4,76,77,78,79,80,81,82,83,84,85,86]
TSA	HDAC inhibitor	Preclinical	Pituitary adenoma, Colorectal carcinoma, HCC	Inhibition	[10, 87,88,89]
Sodium butyrate	HDAC inhibitor	FDA approved	Gastric cancers, Colon carcinoma	Inhibition	[10, 90, 91]
Valproic acid	HDAC inhibitor	FDA approved	Glioma, Bladder cancer, Acute T lymphoblastic leukemia	Inhibition	[10, 92,93,94]
MGCD0103	HDAC inhibitor	Phase II trial	Colon cancer	Inhibition	[10, 95]
Chidamide	HDAC inhibitor	Approved in China	B cell acute lymphocytic leukemia	Inhibition	[10, 96]

ISSN: 1689-1392